Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Review · October 11, 2020

GI Adverse Events With Insulin Glargine/Lixisenatide Fixed-Ratio Combination vs. GLP-1 RAs in T2DM

Diabetes, Obesity & Metabolism


Additional Info

Diabetes, Obesity & Metabolism
Gastrointestinal Adverse Events With Insulin Glargine/Lixisenatide Fixed-Ratio Combination Versus GLP-1 RAs in People With Type 2 Diabetes Mellitus: A Network Meta-Analysis
Diabetes Obes Metab 2020 Sep 29;[EPub Ahead of Print], CK Rayner, T Wu, VR Aroda, C Whittington, S Kanters, P Guyot, A Shaunik, M Horowitz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading